Epitopea Ltd. – Trademark Portfolio
Entity Type: 16
Epitopea Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 1 trademark is registered and 2 are pending. Notable registered marks include CRYPTOMAP. The owner is based in Cambridge.
Station Road
Salisbury House
Cambridge CB12LA , GB
Showing of trademarks Trademarks
Trademark Classifications
Epitopea Ltd.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Epitopea Ltd. have?
Epitopea Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 2 pending.
What trademark classes does Epitopea Ltd. file in?
Epitopea Ltd. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals), Class 44 (Medical Services). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Epitopea Ltd.'s most well-known trademarks?
Epitopea Ltd.'s registered trademark portfolio includes well-known marks such as CRYPTOMAP. These are among 1 currently registered trademark in the portfolio.
What is Epitopea Ltd.'s trademark registration success rate?
Epitopea Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.